Lakefront Biotherapeutics (LKFT) Cash from Investing Activities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 11 years of Cash from Investing Activities data on file, last reported at $72.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $72.0 million, down 19.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.4 million (up 4.07% YoY), and the FY2025 annual result was $336.2 million, up 42.62% from the prior year.
• Cash from Investing Activities fell to $72.0 million in Q1 2026 per LKFT's latest filing, from $84.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $89.1 million in Q1 2025 and troughed at -$1.0 billion in Q1 2022.
• A 5-year average of -$47.8 million and a median of $71.1 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 273.75% in 2022, then surged 344.92% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at $18.5 million in 2022, then surged by 344.92% to $82.2 million in 2023, then decreased by 11.14% to $73.0 million in 2024, then advanced by 15.73% to $84.5 million in 2025, then fell by 14.83% to $72.0 million in 2026.
• Business Quant data shows LKFT's Cash from Investing Activities at $72.0 million in Q1 2026, $84.5 million in Q4 2025, and $66.3 million in Q3 2025.